Biotech innovator Liquidia, specializing in pulmonary therapies, reported a notable insider sale amid continued growth in its ...
New findings reveal pulmonary arterial hypertension may affect the brain early. Learn how inflammation and cognitive decline ...
Jade Biosciences is a pre-revenue biotech focused on JADE101 for IgA nephropathy, offering potential. Read why I rate JBIO ...
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), announced today that ...
In patients with post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction, ...
A University of Alberta research team has found a genetic variant that can be used to identify which patients with pulmonary arterial hypertension need the most urgent care. "This could potentially ...
AllRock Bio, Inc., a clinical-stage biotechnology company focused on advancing impactful therapies for cardiopulmonary and ...
Scientists have created a new "molecular map" uncovering how an important human receptor involved in blood clotting and ...
In a phase 2 trial, treatment with sotatercept shows reduced pulmonary vascular resistance and heart outcomes in patients ...
Positive airway pressure therapy is linked with reduced pulmonary arterial pressures in patients with severe obstructive sleep apnea or obesity hypoventilation syndrome.
Scientists have created a new “molecular map” uncovering how an important human receptor involved in blood clotting and inflammation works—an advance that could help us design better drugs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results